The DOI matches its Crossref record; 360 of the 360 references it cites were found in a registry or an index.
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
Abstract
This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It is intended as a guide for the use of antimicrobial agents in managing patients with cancer who experience chemotherapy-induced fever and neutropenia. Recent advances in antimicrobial drug development and technology, clinical trial results, and extensive clinical experience have informed the approaches and recommendations herein. Because the previous iteration of this guideline in 2002, we have a developed a clearer definition of which populations of patients with cancer may benefit most from antibiotic, antifungal, and antiviral prophylaxis. Furthermore, categorizing neutropenic patients as being at high risk or low risk for infection according to presenting signs and symptoms, underlying cancer, type of therapy, and medical comorbidities has become essential to the treatment algorithm. Risk stratification is a recommended starting point for managing patients with fever and neutropenia. In addition, earlier detection of invasive fungal infections has led to debate regarding optimal use of empirical or preemptive antifungal therapy, although algorithms are still evolving. What has not changed is the indication for immediate empirical antibiotic therapy. It remains true that all patients who present with fever and neutropenia should be treated swiftly and broadly with antibiotics to treat both gram-positive and gram-negative pathogens. Finally, we note that all Panel members are from institutions in the United States or Canada; thus, these guidelines were developed in the context of North American practices. Some recommendations may not be as applicable outside of North America, in areas where differences in available antibiotics, in the predominant pathogens, and/or in health care–associated economic conditions exist. Regardless of venue, clinical vigilance and immediate treatment are the universal keys to managing neutropenic patients with fever and/or infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other studies, however, did not observe an association between antimicrobial timing and mortality (112-117).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [113]
In the citing paper
“patients with febrile neutropenia who fail to defervesce after 4–7 days of broad-spectrum antibacterial therapy are at increased risk of having fungal disease (Table 2) [175, 176].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [175]
Citations
Cites
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Self-citationSiegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.007 · Cited by 3,456
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationBODEY, G. P., BUCKLEY, M., SATHE, Y. S., & FREIREICH, E. J. (1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-2-328 · Cited by 2,469
World Health Organization classification of tumors
Kleihues, P., & Sobin, L. H. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12<2887::aid-cncr32>3.0.co;2-f · Cited by 2,377
Guideline for hand hygiene in health-care settings
Boyce, J. M., & Pittet, D. (2002) · American Journal of Infection Control · doi:10.1067/mic.2002.130391 · Cited by 2,120
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Self-citationPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Self-citation
Research works printed but not linked: 7
- Owens, 2000, Reduction in vancomycin consumption in patients with fever and neutropenia, Clin Infect Dis, 31, 291
- Rotstein, 1997, Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis, Opin Oncol, 4, 2
- Pasqualotto, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613 · DOI
- Ito, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613 · DOI
- Greene, 2007, Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign, Clin Infect Dis, 44, 373, 10.1086/509917 · DOI · Paper page
- Marks, 2009, Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients [abstract M-1249a]
- National Cancer Center Network (NCCN), 2009, Myeloid growth factors: NCCN practice guidelines
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citation
Metadata
- Authors
- Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R.
- Affiliations
- University of Nebraska Medical Center (US)
- CancerCare Manitoba (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Fred Hutch Cancer Center (US)
- City Of Hope National Medical Center (US)
- University of Rochester Medicine (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Minnesota (US)
- University of Florida (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-15
- Volume
- 52
- Issue
- 4
- Pages
- e56-e93
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2123859227
- Semantic Scholar
- 61f444a63e765b8981339be50b8136ae0b15cb08
- Cited by
- 3,463
- References
- 360
- Citations by year
- 2026: 176 · 2025: 180 · 2024: 163 · 2023: 211 · 2022: 233 · 2021: 245 · 2020: 260 · 2019: 277 · 2018: 254 · 2017: 267 · 2016: 218 · 2015: 247 · 2014: 248 · 2013: 221 · 2012: 174
- FWCI
- 112.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- febrile neutropenia, cancer, chemotherapy-induced neutropenia, antibiotic prophylaxis, antifungal prophylaxis, antiviral prophylaxis, risk stratification, invasive fungal infections, preemptive antifungal therapy, empirical antibiotic therapy, infection management
- MeSH terms
- Anti-Infective Agents, Antineoplastic Agents, Canada, Communicable Diseases, Fever of Unknown Origin, Humans, Neoplasms, Neutropenia, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. https://app.cochat.ai/papers/10.1093/cid/cir073
- The paper
- Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cir073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.